Afuco™ Anti-Human IL2RA ADCC Therapeutic Antibody (HuMax-TAC), ADCC Enhanced
Anti-IL2RA ADCC Enhanced Antibody (HuMax-TAC) is an ADCC enhanced antibody produced by our Afuco™ platform. HuMax-TAC specifically targets the TAC antigen and strongly inhibits IL-2 binding to the IL-2R and antigen-induced T cell proliferation. It is used for the treatment of acute renal transplant rejection and has been in development for the treatment of T cell leukemia, multiple sclerosis, graft-versus-host disease, ulcerative colitis, uveitis and asthma.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-407CL |
| Pricing | Inquiry |
| Host | Human |
| Target | IL2RA |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | ≤6 months at 4°C; ≥6 months at -20°C. |